Podcasts about Synthetic biology

Send us Fan MailWhat if medicines could actually “decide” when and where to activate inside the body? MIT-trained synthetic biologist Dr. Jacob Becraft, Ph.D. is building programmable therapies that behave less like traditional drugs…and more like biological software.Dr. Becraft is Co-Founder and CEO of Strand Therapeutics ( https://www.strandtx.com/ ), a company pioneering what may become one of the next great frontiers in medicine: programmable mRNA therapeutics.Long before mRNA became a household term through COVID vaccines, Dr. Becraft and his colleagues at MIT were developing what has been described as the world's first synthetic biology programming language for mRNA - technology designed not simply to deliver genetic instructions, but to create logic-driven therapies capable of making decisions inside living cells.Now Strand is translating that vision into cancer therapeutics, with early clinical data from its lead candidate STX-001 showing responses in patients with advanced solid tumors who had exhausted conventional options - including evidence of systemic immune activity and even complete responses.Beyond the science, Jake is also a leading voice in synthetic biology, biotech entrepreneurship, and the future relationship between software, biology, and medicine.#StrandTherapeutics #JacobBecraft #SyntheticBiology #mRNA #ProgrammableMedicine #CancerImmunotherapy #Immunotherapy #Biotech #PrecisionMedicine #GeneTherapy #SyntheticBiologyEngineering #FutureOfMedicine #Oncology #CAR_T #mRNATherapeutics #Bioengineering #IL12 #RNA #MIT #CellTherapy #Longevity #Biotechnology #MedicalInnovation #NextGenMedicine #CancerResearch #AIinBiology #HealthcareInnovation #GeneticMedicine #ScientificBreakthrough #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailWe used to think of DNA as something we read. Now we're starting to treat it like something we write - and that changes everything about how medicine gets made.Dr. Patrick Finn, Ph.D. is President and COO of Twist Bioscience ( https://www.twistbioscience.com/ ), a company that's helping turn biology into something you can engineer, iterate, and even industrialize. Dr. Finn has spent his entire career building the infrastructure layer of modern biotech - from sequencing and sample prep at Beckman Coulter and Invitrogen, to scaling commercial platforms at Agilent Technologies and now Twist.Dr. Finn also served as Vice President of Sales and Marketing for Enzymatics (recently acquired by QIAGEN), leading commercial activities for North America and Europe, delivering significant top line growth and expanding the base of business to business customers.So this isn't just a conversation about the future - it's about how the tools that make the future possible are actually built and deployed.On this episode we go beyond the buzzwords and dig into what it really means to “program biology”, and how close we actually are to designing medicines the way we design software.In addition to his role at Twist, Dr. Finn currently serves on the Scientific Advisory Board of Lasergen and previously served on the Scientific Advisory Board of Enzymatics. He holds a PhD in Nucleic Acid Chemistry from Southampton University and a BSc Hons in Chemistry from Heriot-Watt University.#SyntheticBiology #Biotech #DrugDiscovery #AIinHealthcare #ArtificialIntelligence #DNA #Genomics #Bioengineering #ProgrammableBiology #CRISPR #GeneTherapy #Biotechnology #LifeSciences #MachineLearning #AIResearch #PharmaInnovation #Biology #SciencePodcast #FutureOfMedicine #Biodesign #SyntheticDNA #GenomeSequencing #Bioeconomy #DeepTech #HealthTechSupport the show

Episode Synopsis:Are the rising health issues across the West just the result of a sedentary lifestyle and Standard American Diet, or are we being intentionally poisoned as part of a larger endgame strategy?We talk about this and much more, including:​How are they using cellular technology to feed us “food product?”​What are some things we can do to grow healthy food?​How is DARPA using “negative light” to send secret messages inside of heat?​Why is it imporant to understand systems of evil?​How are they adding poisin coating to the seeds of our fod?​Why is a relationship with Yeshuah crucial for surviving the world we live in Original Air DateMay 6th, 2026Special GuestCeleste Solum – Producer of the Celestial ReportInsperational Homestead RecipesPDR for Herbal Medicine PDR for Herbal Medicine – online PDFDr. Chase's 1885 EditionShow HostsJason Spears & Christopher DeanOur PatreonConsider joining our Patreon Squad and becoming a Tier Operator to help support the show and get access to exclusive content like:​Links and Resources​Studio Notes​A monthly Zoom call with Jason and Christopher ​And More…ORP ApparelMerch StoreConnect With UsLetsTalk@ORPpodcast.comFacebookInstagram

The containment has failed. The wave is here.In the inaugural episode of our intensive three-part deep dive, The Soul Trap breaks open the seal on one of the most prophetic and unsettling manifestos of our time: "The Coming Wave" by Mustafa Suleyman and Michael Bhaskar.We aren't just talking about "new tech"—we are talking about the final acceleration. For decades, we've played with the fire of silicon and code, but as Suleyman warns, we are now approaching a threshold of unprecedented power that threatens to slip the leash of human control.In This Episode, We Explore:The Proliferation of the Infinite: A brief, high-level overview of Suleyman's thesis on why this wave—driven by AI and Synthetic Biology—is unlike any industrial revolution in human history.The Architects of the Mind: A heavy focus on Large Language Models (LLMs). We peel back the curtain on how these digital oracles are being trained on the sum of human knowledge to reshape reality, truth, and the very nature of the human soul.The Eschatological Signal: How the rapid "intelligence explosion" aligns with ancient warnings of the End Times. Is the LLM the foundation for a global system of deception?The Dilemma of Containment: Why the creators of this technology admit it may be impossible to turn off, and what that means for a world teetering on the edge of the Great Reset.#AGI2026 #TheContainmentProblem #ImageOfTheBeasthttps://www.thesoultrap.com/Podcast: https://thesoultrap.buzzsprout.com/#TheComingWave #TheSoulTrap #MustafaSuleyman #TheDigitalLeviathan #IntelligenceExplosion #LLM #GenerativeAI #AGI2026 #ArtificialIntelligence #SyntheticBiology #TheContainmentProblem #TechnologicalSingularity #EndTimes #BibleProphecy #Revelation13 #ImageOfTheBeast #DigitalDeception #SpiritualVigilance #Eschatology #TheGreatResetSupport the show

Michael Jewett is a pioneer of cell-free biotechnology. Instead of using living microbes as factories, he uses their internal molecular machinery to make valuable proteins, medicines, diagnostics, and other chemicals. Jewett recently used the technique for vaccine production in an approach that could produce up to 150,000 doses from one liter. He believes cell-free biotech could democratize the production of essential medicines, improve water safety, and help convert atmospheric carbon into useful products, among other promising possibilities. “It's just-add-water biotechnology,” Jewett tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Michael Christopher Jewett Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces Mike Jewett, a professor of bioengineering and chemical engineering at Stanford University. (00:03:23) What Is Cell-Free Biotechnology? Using the internal machinery of cells without the cells themselves. (00:04:20) Removing “Evolutionary Baggage” Why cells' natural priorities can conflict with engineering goals. (00:07:41) Advantages of Cell-Free Systems From large-scale production to decentralized, on-demand manufacturing. (00:11:40) Making Proteins Outside Cells How DNA instructions are used to produce functional proteins. (00:13:49) Biosensors for Water Safety Detecting contaminants like lead using engineered proteins. (00:17:05) Engineering Better Sensors Improving sensitivity and selectivity through protein design. (00:20:33) AI in Bioengineering How data and models accelerate discovery and design. (00:23:22) Sustainability & Carbon Capture Turning atmospheric carbon into useful chemicals. (00:26:18) Building New Biological Pathways Combining chemistry and biology to create novel production systems. (00:27:54) From Molecules to Materials How acetyl-CoA enables fuels, plastics, and other products. (00:30:51) Teaching Biotechnology Making biotech accessible through hands-on, “just-add-water” kits. (00:33:12) Future In a Minute Rapid-fire Q&A: innovation, collaboration, and the future of biotech. (00:35:32) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore China's burgeoning role in the synthetic biology sector, as outlined in a recent article discussing China's strategic focus on biotechnology within its latest five-year plan. This strategy identifies biomanufacturing, particularly synthetic biology and genetic engineering, as pivotal for China's emerging bioeconomy. The nation's approach frames biology as a transformative industrial platform poised to reshape pharmaceuticals, materials science, agriculture, and energy industries. Central to this transformation is DNA synthesis, which allows for the design and manufacture of genetic sequences. As China rapidly expands its synthetic biology capabilities, questions arise about its potential to become an innovation powerhouse, the competitiveness of Chinese firms in DNA synthesis, and geopolitical factors affecting international cooperation and supply chains. Insights from industry leaders highlight China's unique industrialization strengths. The country excels in rapidly scaling technologies due to its ability to mobilize capital, infrastructure, and manufacturing swiftly—a capability that surpasses Europe and the U.S. This aligns with China's national biomanufacturing strategy aimed at developing vast production systems across pharmaceuticals and industrial biotechnology. Beyond sheer manufacturing capacity, China is constructing a comprehensive ecosystem to bolster advanced biotechnology. The nation's development of clinical infrastructure and pharmaceutical manufacturing is noteworthy. China is actively exploring personalized therapies and building regulatory pathways for advanced treatments, signaling a potential shift in global biotech dynamics. Domestically, Chinese companies are developing technology platforms to reduce dependence on imported equipment and Western supply chains. The competitive landscape in DNA synthesis is evolving beyond traditional commodity-versus-innovation narratives, as both Chinese and Western companies pursue similar technological advancements. However, geopolitical tensions complicate collaborations between Chinese and Western firms. Export controls highlight the growing barriers to cooperation. Despite price competitiveness from Chinese DNA synthesis providers, concerns over data security and regulatory risks are prompting some Western buyers to favor suppliers from Europe or the US. Shifting gears to regulatory matters, recent developments highlight a dynamic industry characterized by scientific advancements, regulatory shifts, legal battles, and strategic corporate maneuvers. Central to these is the call for enhanced transparency and evidence standards in the FDA's accelerated approval pathway. Strengthening evidence requirements aims to ensure that drugs approved under this pathway are supported by robust scientific data, ultimately safeguarding patient health and maintaining public trust in regulatory institutions. A landmark financial event has unfolded with Kailera Therapeutics' record-breaking IPO, raising $625 million to bolster its obesity treatment pipeline. This significant capital inflow not only sets a new benchmark for biotech IPOs but also underscores burgeoning interest in addressing obesity—an area with substantial unmet medical needs. In legal arenas, Teva Pharmaceuticals scored a victory as an appeals court revived a $177 million verdict against Eli Lilly concerning patent disputes over migraine medications. Additionally, Viatris and Teva have initiated recalls due to issues with drug dissolution and raw material approvals. The appointment of Dr. Erica Schwartz as the potential Director of the CDC marks another pivotal moment. Her leadership could steer the CDC towards more effective public health responses. On a broader industry scale, there is anSupport the show

Most people still treat climate solutions as a cost.Wanwipa Siriwatwechakul argues that this is exactly why so many leaders miss the real opportunity.The next industrial era will not be built by patching old systems, but by redesigning them from the ground up.In this episode of Beginner's Mind, Wanwipa explains why industrial decarbonization is not mainly about sacrifice, compliance, or adding expensive fixes to yesterday's infrastructure. It is about building better systems, stronger companies, and entirely new categories of value creation.A chemical engineer trained at MIT and Princeton, former professor, and Partner at Vectors Capital, Wanwipa works at the intersection of climate tech, synthetic biology, industrial innovation, and early-stage venture capital. Her perspective is grounded in both science and scale: what matters is not only whether a breakthrough works in the lab, but whether it can survive the journey from one gram to one ton, from prototype to product, from curiosity to adoption.We talk about why the strongest climate companies redesign industries instead of decorating old ones, why synthetic biology is emerging as a new industrial toolkit, how startups like Huue Bio, Ingrediome, and Solidec reveal very different scale-up strategies, and why the best founders treat breakthroughs as hypotheses to test rather than theories to defend.As Wanwipa puts it:(01:57:02) “See climate solutions not as cost, but as funding the next industrial era.” What you'll hear in this episodeWhy decarbonization becomes far more powerful when industries are redesigned, not merely optimized How synthetic biology can replace toxic, waste-heavy industrial chemistry with cleaner production models Why great science is only the starting point, and why scale is where most companies really live or die What founders can learn about resilience, coachability, timing, and relentless customer discovery How climate tech can create competitive advantage, new revenue streams, and distributed industrial resilience Why Southeast Asia may become a powerful region for the next wave of climate and bioindustrial growth Selected moments(00:00:56) From Professor to Climate Tech Venture Capital(00:09:27) Why Climate Change Became Personal in Thailand(00:14:11) From Pure Discovery to Real Market Impact(00:23:00) Decarbonization by Redesigning Industry(00:30:06) The Climate Tech Mistake Costing Investors Money(00:34:17) Solidec and the Future of Distributed Manufacturing(00:38:50) Why Big Companies Resist Industrial Reinvention(00:46:21) How Great Founders Turn Pivots Into New Markets(00:50:50) Customer Discovery in Deep Tech and Climate Startups(00:53:08) Great Science Must Become Products People Use(01:00:39) Synthetic Biology as the New Industrial Toolkit(01:10:15) How Climate Startups Find Early Adopters(01:13:19) Founder Resilience and the Stomach of Steel(01:21:15) Venture Capital and the Crucial Why Now(01:57:02) Climate Solutions as Funding the Next Industrial Era Follow the show for more long-form conversations on technologySend us Fan Mail Join Christian Soschner for expert coaching. 50% Off - With 35+ years in deep tech, startups/scaleups, and public companies, Christian offers power video sessions. Elevate strategy, execution, and leadership. Book Now.Support the showJoin the Podcast Newsletter: Link

We're entering a world where life itself could become programmable.What if creating new forms of life becomes as simple as writing code? Geneticist Adrian Woolfson explains how close we are — and why the consequences could be extraordinary.--------------------------Exciting news!We've been nominated for a Webby Award—one of the top honors in podcasts. If you enjoy the show, please take a moment to vote. It's quick and it really helps: 

April is Earth Month, and in appreciation of the plant life all around us, we're re-running a conversation we had with Beth Sattely last year on the future of plant chemistry. Beth reminds us that plants are more than food or pretty things to look at — they have the potential to help us fight climate change or even cancer. We hope you'll take another listen and join us in learning more about how plants can positively impact environmental and human health. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Elizabeth Sattely Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Beth Sattely, a professor of chemical engineering at Stanford University. (00:01:28) Path to Plant Metabolism How chemistry and gardening led to a career in plant science. (00:02:12) Environmental & Human Health Using plants to improve both the planet and people's well-being. (00:03:11) Engineering Climate-Resilient Crops Making crops more sustainable and nutritious amid global change. (00:04:16) Old vs. New Crop Engineering Comparing traditional breeding with modern molecular tools. (00:06:22) Industry & Long-Term Food Security The gap between short-term market goals and long-term environmental needs. (00:07:31) Tomato Chemistry Tomatoes reveal how plants produce protective molecules under stress. (00:10:44) Plant “Vaccines” & Immune Signaling How plants communicate threats internally and mount chemical defenses. (00:12:32) Citrus Greening & Limonoids The potential role of limonoid research on citrus greening. (00:15:17) Plants Making Medicine How plants like Yew trees naturally produce cancer drugs like Taxol. (00:19:37) Diet as Preventative Medicine Identifying plant molecules to understand their preventative health effects. (00:22:54) Food Allergies & Plant Chemistry Why the immune system tolerates some foods and rejects others. (00:25:00) Understanding Tolerance in Immunity Possibility of reintroducing tolerance through partial molecular exposure. (00:26:20) Engineering Healthier Plants Potential for designing plants to enhance micronutrient content. (00:27:58) Training the Next Generation Beth celebrates her students' role in shaping a sustainable future. (00:28:57) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join Michael Newton, CEO of Qorium, for a visionary conversation on the power of synthetic biology to reshape our material world. With a track record of scaling products to over $1 billion in annual turnover at Nike, Michael is now leading the charge in cellular agriculture. In this episode, we explore the immense promise of synthetic biology, why Qorium's unique approach to lab-grown leather is a game-changer for the planet, and how we can re-engineer global value chains for a sustainable future.

In this episode of the Crazy Wisdom podcast, host Stewart Alsop sits down with Markus Buehler, the McAfee Professor of Engineering at MIT, to explore how seemingly different systems—from proteins and music to knowledge structures and AI reasoning—share underlying patterns through hierarchy, self-organization, and scale-free networks. The conversation ranges from the limits of current AI interpolation versus true discovery (using the fire-to-fusion example), to the emergence of agent swarms and their non-linear effects, to practical questions about ontologies, knowledge graphs, and whether humans will remain necessary in the creative discovery process. Markus discusses his lab's work automating scientific discovery through AI agents that can generate hypotheses, run simulations, and even retrain themselves, while Stewart shares his own experiences building applications with AI coding agents and grapples with questions about intellectual property, material science constraints, and the future of human creativity in an AI-abundant world.Timestamps00:00 - Introduction to Marcus Buehler's work on knowledge graphs, structural grammar across proteins, music, and AI reasoning05:00 - Discussion of AI discovery versus interpolation, using fire and fusion as examples of fundamental versus incremental innovation10:00 - Language models as connective glue between agents, enabling communication despite imperfect outputs and canonical averaging15:00 - Embodiment and agency in AI systems, creating adversarial agents that challenge theories and expand world models20:00 - Emergent properties in materials and AI, comparing dislocations in metals to behaviors in agent swarms25:00 - Human role-playing and phase separation in society, parallels to composite materials and heterogeneity30:00 - Physical world challenges, atom-by-atom manufacturing at MIT.nano, limitations of lithography machines35:00 - Synthetic biology as alternative to nanotechnology, programming microorganisms for materials discovery40:00 - Intellectual property debates, commodification of AI models, control layers more valuable than model architecture45:00 - Automation of ontologies, agent self-testing, daughter's coding success at age 1150:00 - Graph theory for knowledge compression, neurosymbolic approaches combining symbolic and neural methods55:00 - Nonlinear acceleration in AI, emergence from accumulated innovations, restaurant owner embracing AI01:00:00 - Future generations possibly rejecting AI, democratization of knowledge, social media as real-time scientific discourseKey Insights1. Universal Patterns Across Disciplines: Seemingly different systems in nature—proteins, music, social networks, and knowledge itself—share fundamental structural patterns including hierarchy, self-organization, and scale-free networks. This commonality allows creative thinkers to draw insights across disciplines, applying principles from one domain to solve problems in another. As an engineer and materials scientist, Buehler has leveraged these isomorphisms to advance scientific understanding by mapping the "plumbing" of different systems onto each other, revealing hidden relationships that enable extrapolation beyond what's observable in any single domain.2. The Discovery Versus Interpolation Problem: Current AI systems, particularly large language models, excel at interpolation—recombining existing knowledge in new ways—but struggle with genuine discovery that requires fundamental rewiring of world models. Using the example of fire versus fusion, Buehler explains that an AI trained on combustion chemistry would propose bigger fires or new fuels, but couldn't conceive of fusion because that requires stepping back to more fundamental physics. True discovery demands the ability to recognize when existing theories have boundaries and to develop entirely new frameworks, something current AI architectures aren't designed to achieve due to their training objective of predicting the most likely outcome.3. The Role of Ontologies and Knowledge Graphs: While some AI researchers argue that ontologies are unnecessary because models form internal representations, Buehler advocates for explicit knowledge graphs as essential discovery tools. External ontologies provide sharp, analytical, symbolic representations that complement the fuzzy internal representations of neural networks. They enable verification of rare connections—like obscure papers that might hold key insights—which would be averaged away in standard AI training. This neurosymbolic approach combines the generalization capabilities of neural networks with the precision of formal knowledge structures, creating more powerful discovery systems.4. Emergent Properties and Agent Swarms: Just as materials science shows that collections of atoms exhibit properties impossible to predict from individual components, AI agent swarms demonstrate emergent behaviors beyond single models. When agents are incentivized not just to answer questions but to challenge each other adversarially, propose theories, and test hypotheses, they can spawn new copies of themselves and evolve understanding beyond their initial programming. This emergence isn't surprising from a materials science perspective—dislocations, grain boundaries, and other collective phenomena only appear at scale, fundamentally determining material behavior in ways unpredictable from studying just a few atoms.5. The Commoditization of Intelligence: The fundamental AI models themselves are becoming commodities, as evidenced by events like the Moldbug phenomenon where people built agents using various providers interchangeably. The real value is shifting from who has the smartest model to how models are orchestrated, integrated, and deployed. This parallels historical technology adoption patterns—just as we moved past debating who makes the best electricity to focusing on applications, AI is transitioning from a horse race over model capabilities to questions of infrastructure, energy, access speed, and agent coordination at the systems level.6. Human-AI Collaboration and Creative Control: Rather than wholesale replacement, AI enables humans to operate in an intensely creative space as orchestrators sampling from vast possibility spaces. Similar to how Buehler's 11-year-old daughter now builds sophisticated applications that would have required professional developers years ago, AI democratizes access to capabilities while humans retain the creative judgment about direction and meaning. The human role becomes curating emergence, finding rare connections, playing at the edges of knowledge, and exercising the kind of curiosity-driven exploration that AI systems lack without embodied stakes in their own survival and continuation.7. Technology as Evolutionary Inevitability: The development of AI represents not an unnatural threat but the next stage of human evolution—an extension of our innate drive to build models of ourselves and our world. From cave paintings to partial differential equations to artificial intelligence, humans continuously create increasingly sophisticated representations and tools. Attempting to stop this technological evolution is futile; instead, the focus should be on steering it ...

This episode with Dr Tae Seok Moon explores how synthetic biology is rapidly transforming medicine, climate innovation, and industrial production, while introducing new layers of international risk, ethical tension, and governance challenges. We examine how engineered biology is already being used to fight disease, reduce emissions, and address pollution, alongside growing concerns about dual-use risk, biosecurity, and the accessibility of powerful biological tools. The discussion looks at the limits of existing global governance frameworks, including the Biological Weapons Convention, and what it means to regulate technologies that evolve faster than law and policy. We also unpack whether synthetic biology is becoming a new domain of geopolitical competition, and why international collaboration, rather than purely national competition, may be essential to managing risk at scale.Dr Moon is a leading researcher and practitioner in synthetic biology, working at the intersection of science, policy, and global collaboration. He is a professor, entrepreneur, and Director of a National Science Foundation Global Center, with extensive experience in biomanufacturing, climate applications, and medical innovation. His work focuses on translating cutting-edge biological engineering into real-world solutions, while actively engaging on biosafety, biosecurity, ethical oversight, and the need for inclusive global governance as synthetic biology reshapes the future of risk and opportunity.The International Risk Podcast brings you conversations with global experts, frontline practitioners, and senior decision-makers who are shaping how we understand and respond to international risk. From geopolitical volatility and organised crime, to cybersecurity threats and hybrid warfare, each episode explores the forces transforming our world and what smart leaders must do to navigate them. Whether you're a board member, policymaker, or risk professional, The International Risk Podcast delivers actionable insights, sharp analysis, and real-world stories that matter.The International Risk Podcast is sponsored by Conducttr, a realistic crisis exercise platform. Conducttr offers crisis exercising software for corporates, consultants, humanitarian, and defence & security clients. Visit Conducttr to learn more.Dominic Bowen is the host of The International Risk Podcast and Europe's leading expert on international risk and crisis management. As Head of Strategic Advisory and Partner at one of Europe's leading risk management consulting firms, Dominic advises CEOs, boards, and senior executives across the continent on how to prepare for uncertainty and act with intent. He has spent decades working in war zones, advising multinational companies, and supporting Europe's business leaders. Dominic is the go-to business advisor for leaders navigating risk, crisis, and strategy; trusted for his clarity, calmness under pressure, and ability to turn volatility into competitive advantage. Dominic equips today's business leaders with the insight and confidence to lead through disruption and deliver sustained strategic advantage.The International Risk Podcast – Reducing risk by increasing knowledge.Follow us on LinkedIn and Subscribe for all our updates!Tell us what you liked!

One on One Video Call W/George https://tidycal.com/georgepmonty/60-minute-meetingSupport the show:https://www.paypal.me/Truelifepodcast?locale.x=en_US

The 2025 International Mars Society Convention convened at the University of Southern California this October for three days of passionate discussion about humanity’s future on the red planet. Speakers explored science, policy, technology, AI, synthetic biology, and the long-term path toward becoming a multi-planet species. In this episode, Mat Kaplan, senior communications adviser at The Planetary Society, shares his conversations with speakers and guests at the Convention. We hear from Robert Zubrin, founder of The Mars Society, who delivered a fiery call to protect NASA’s science programs in the face of unprecedented budget cuts. Humphrey “Hoppy” Price, Chief Engineer for NASA’s Robotic Mars Exploration Program at the Jet Propulsion Laboratory, updates us on the future of Mars Sample Return and new mission architectures. Keynote speaker Dex Hunter-Torricke, a longtime communications leader for SpaceX, Meta, and other major tech organizations, reflects on AI’s promise and peril, and why Mars remains a beacon of hope for humanity’s future. Biologist and technologist Tiffany Vora, vice president for innovation partnerships at Explore Mars, and Erika DeBenedictis, biologist and founder of Pioneer Labs, reveal breakthroughs in synthetic biology and engineered microbes that could help future Martians survive. Steve Benner, chemist and founder of the Foundation for Applied Molecular Evolution (FfAME), revisits the Viking lander experiments and makes a provocative case that we may have found Martian life nearly 50 years ago. Architect Melodie Yashar, CEO of AENARA and a pioneer in 3D-printed habitat research, shares progress in additive construction on Earth and Mars. James Burk, executive director of The Mars Society, discusses advocacy, analog research stations, and the organization’s expanding international footprint. Finally, we meet Sasha, a 13-year-old presenter whose enthusiasm offers a bright glimpse of the next generation of explorers. We wrap up the show with What’s Up with Bruce Betts, chief scientist at The Planetary Society, with a discussion of perchlorates in the Martian soil. Discover more at: https://www.planetary.org/planetary-radio/2025-mars-society-conventionSee omnystudio.com/listener for privacy information.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we're diving into a fascinating exploration of how the biotechnology industry might evolve by adopting a model inspired by Japan's keiretsu system. This concept, known as "biokeiretsu," is being proposed as a transformative strategy to address the structural inefficiencies that hinder the growth of biotech ventures today.To understand the potential impact of this model, we first need to consider the current landscape of the biotechnology sector. Despite rapid scientific advances, biotechnology struggles to scale effectively. This challenge is reminiscent of how petrochemicals became foundational in the 20th century. The sector is marked by deep fragmentation, with research, venture creation, and manufacturing often operating in silos. This isolation not only duplicates efforts but also slows down market adoption.Currently, enabling technologies like automation and data tools are primarily geared towards pharmaceutical clients. This leaves synthetic biology ventures grappling with inadequate platforms to support their growth. One critical issue identified in this landscape is the misalignment between venture capital interests and the inherently long-term nature of industrial biotechnology development. Investors frequently favor projects that promise quick returns, such as therapeutic endeavors, over those that require heavy infrastructure investment. This scenario creates what some refer to as an "hourglass economy," where there is plenty of funding for early research and late-stage commercialization, but a bottleneck occurs in the middle stages where scaling should take place.The biokeiretsu model proposes an integrated industrial architecture aimed at resolving these issues by aligning innovation, capital, and industry through shared infrastructure and coordinated scaling. The model emphasizes vertical coordination across value chains and horizontal efficiency through shared capabilities like data systems and regulatory platforms. By doing so, it seeks to reduce duplication and accelerate time-to-market for new biotechnologies.In addition to operational efficiencies, biokeiretsu stresses geographic flexibility—production should happen where it's most economically viable while retaining innovation and intellectual property in regions best suited for these activities. This approach encourages national specialization within a globally interconnected framework, promoting cooperation over protectionism.Governance within this model involves cross-equity stakes, shared services, and pooled contracts to align incentives among investors, start-ups, corporates, and governments. By reinforcing interdependence rather than competition, this structure aims to create a more cohesive industrial ecosystem. Investors play a crucial role by allocating capital along entire value chains rather than scattering it across unrelated start-ups.Start-ups benefit significantly from shared infrastructure, which allows them to concentrate on product-market fit rather than compliance or plant construction. Corporate partners act as demand anchors, offering early validation and de-risking innovation through agreements that guarantee offtake. The enabling layer of automation and design tools forms a connective tissue between discovery and production, ensuring that capacity evolves alongside demand.Governments are also instrumental in this framework by co-investing in shared infrastructure and setting strategic mission priorities focused on building long-term capability and resilience rather than just short-term job creation.Implementation of this model begins with small-scale experiments in coordination among synergistic start-ups. OvSupport the show

In this episode of EBRC In Translation, we are joined with Danielle Tullman-Ercek, a professor of chemical and biological engineering at Northwestern University and co-director of its Center for Synthetic Biology. Danielle discusses her journey from aspiring architect to leading bioengineer, the foundation and goals of her lab, the interdisciplinary approach at Northwestern's Center for Synthetic Biology, and the inception of her company, Opera Bioscience. She also shares insights on navigating academia and entrepreneurship, the impact of federal research funding challenges, and the importance of community and collaboration in scientific research. Keep updated with GRC Physics of Viruses and Protein Cages and ECI Biochemical and Molecular Engineering XXIV.For more information about EBRC: Visit our website at ebrc.org. If you are interested in getting involved with the EBRC Student and Postdoc Association, fill out a membership application for graduate students and postdocs or for undergraduates and join today! Transcription:Episode transcripts are the unedited output from Whisper and likely contain errors.

We've entered a new age. Where nature once took a million years to make a few genetic changes, scientists can now make billions in an afternoon — and even imagine adapting humans for life beyond Earth.George Church, a Harvard geneticist, pioneer of the Human Genome Project, and founder of more than 50 biotech companies, helped lay the foundation for CRISPR, personal genomics, and even de-extinction.In this episode, he explains how biotechnology, AI, and materials science are converging to transform life itself -  from reversing aging and curing disease to resurrecting lost species like the woolly mammoth, and one day, helping humanity thrive among the stars.

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?David: Unlocking potential.Biotech startups face daunting challenges, but David Kiewlich, Founder and CEO of Tomorrow Biotech Corporation, has created a model that flips the odds. While most startups face a 90% failure rate, David's incubator, Badass Labs, boasts an astounding 95% success rate.The secret? David's incubator takes on time-consuming tasks and provides founders with the tools and support they need to focus on high-value activities. “We take what I call low-value, high-risk tasks off of the responsibility of these early founders,” David explained. By handling procurement, accounting, and regulatory compliance, the incubator saves startups time, money, and frustration.For example, David shared how the incubator's full-service procurement system saves companies more than 70 hours of work while also cutting costs. “Because it's a pooled spend model, it allows us to be one giant customer instead of many little ones,” he said. This approach not only improves efficiency but also doubles the runway for many startups.David's focus goes beyond logistics—he's also deeply invested in coaching founders to grow. He emphasized the importance of coachability, saying, “If they are open to guidance and comfortable with being vulnerable, they'll grow.” This hands-on support ensures founders avoid rookie mistakes, expand their skill sets, and present their companies as professional and investor-ready.The work being done at Badass Labs and Tomorrow Biotech isn't just about improving success rates—it's about saving lives. By accelerating the development of biotech innovations, David's incubator is paving the way for groundbreaking ideas to reach the market faster.If you're inspired by David's approach and want to learn more about his incubator, visit badasslabs.org. With multiple locations across the U.S. and plans to expand, the program is open to biotech, climate tech, and other transformative startups. By helping founders focus on what matters most, David is proving that with the right support, startups can defy the odds and change the world.tl;dr:David Kiewlich's incubator flips the biotech startup success rate from 10% to 95% with unique support.The program removes tedious tasks, saving founders time and enabling them to focus on execution.Coachability is critical—David helps founders grow by fostering their confidence and guiding their development.David shared a superpower: unlocking potential by building up others and inspiring action.Tomorrow Biotech and Badass Labs accelerate innovation, empowering founders to bring life-saving ideas to market.How to Develop Unlocking Potential As a SuperpowerDavid Kiewlich's superpower is his ability to unlock the potential in others by fostering their confidence and helping them grow into their best selves. Reflecting on his life, David shared how he developed this skill early on, saying, “You become sort of focused on how you can lift up and protect everyone around you.” He uses this mindset to empower biotech founders, helping them become “superhumans” who think bigger, execute better, and achieve more.One inspiring story David shared highlights his superpower in action. Years ago, he organized a grassroots effort to rescue surplus food from wholesalers and deliver it to nonprofits across the San Francisco Bay Area. Over the course of a year, he single-handedly moved nearly 600,000 pounds of produce, ensuring it reached those in need instead of ending up in landfills. By showing what's possible, David inspired others to replicate his efforts, amplifying his impact.To develop this superpower, David suggests:Focus on building up others rather than seeking credit for yourself.Encourage people by expressing belief in their abilities.Help others see what's possible by setting an example.Support people in a way that allows them to focus on their strengths.By following David's example and advice, you can make unlocking potential a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileDavid Kiewlich (he/him):Founder and CEO, Tomorrow Biotech CorporationAbout Tomorrow Biotech Corporation: Tomorrow Biotech Corporation consists of an accelerator fund, an early stage fund and includes the Bay Area Disruptor and Startup Support Labs (BADASS Labs) a 501c3, non-profit series of biotech incubators. While the funds are new, the incubator has been in operation for 6 years, supporting dozens of pre-seed through series B (and beyond) companies. With a track record of 50 of 55 company successes for members of the incubator, this ecosystem has a uniquely successful approach to founder support, which has substantially changed the concept and expectations for early stage incubators. BADASS Labs is more than a 501c3, non-profit biotech incubator that rents lab space to small businesses. It is a strategic ally that empowers biotech entrepreneurs to achieve their full potential. By offering a comprehensive suite of services, such as purchasing, waste management, operations and even health insurance plans for its members, BADASS Labs enables its clients to focus on their core competencies and substantially reduce their operational costs. BADASS Labs bridges the gap between research and commercialization, by facilitating novel technologies from academic, national lab or self-generated sources into viable products that can enhance the domestic supply chain and generate regional employment. While we can incubate companies at any stage, we have a particular focus on the earlier side, from Pre-Seed through Series B stages.Website: badasslabs.org, TomorrowBiotech.com, MissionBoosterProcurement.comBiographical Information: Dr. David Kiewlich (Ph.D. in Cell and Developmental Biology) is a serial founder and entrepreneur in biotech. With over 35 years' experience working for industry, as well as 6 startups of his own (in Oncology, Cell Based Therapies and Synthetic Biology), his background is excellently aligned with the needs and struggles of pre-commercialization startups. He founded and runs Tomorrow Biotech, which includes the Bay Area Disruptor and Startup Support Labs (BADASS Labs) a 501c3, non-profit series of biotech incubators, which has supported dozens of pre-seed through series B (and beyond) companies, as well as a startup and early-stage fund. In addition to Tomorrow Biotech, David is also the CSO of a cell based therapy company, focused on autoimmune disease, advisor for several biotech startups and frequent public speaker advocating for increased sustainability and greater Diversity, Equity and Inclusion (DEI) in the sciences.LinkedIn Profile: linkedin.com/in/davidkiewlichSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, and Rancho Affordable Housing (Proactive). Learn more about advertising with us here to help us Power Up October.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on October 28, 2025, at 1:30 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, November 19, 2025, at 12:00 PM Eastern — Devin Thorpe, CEO and Founder of The Super Crowd, Inc., will lead a session on “Investing with a Self-Directed IRA.” In this session, Devin will explain how investors can use self-directed IRAs to participate in regulated investment crowdfunding while managing taxes and optimizing returns. He'll break down when this strategy makes sense, how to choose the right custodian, and what fees, rules, and risks to watch for. With his trademark clarity and real-world experience, Devin will help you understand how to balance simplicity with smart tax planning—so you can invest confidently, align your portfolio with your values, and make your money work harder for both impact and income.SuperGreen Live, January 22–24, 2026, livestreaming globally. Organized by Green2Gold and The Super Crowd, Inc., this three-day event will spotlight the intersection of impact crowdfunding, sustainable innovation, and climate solutions. Featuring expert-led panels, interactive workshops, and live pitch sessions, SuperGreen Live brings together entrepreneurs, investors, policymakers, and activists to explore how capital and climate action can work hand in hand. With global livestreaming, VIP networking opportunities, and exclusive content, this event will empower participants to turn bold ideas into real impact. Don't miss your chance to join tens of thousands of changemakers at the largest virtual sustainability event of the year.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Impact Accelerator Summit is a live, in-person event taking place in Austin, Texas, from October 23–25, 2025. This exclusive gathering brings together 100 heart-centered, conscious entrepreneurs generating $1M+ in revenue with 20–30 family offices and venture funds actively seeking to invest in world-changing businesses. Referred by Michael Dash, participants can expect an inspiring, high-impact experience focused on capital connection, growth, and global impact.If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?David: Unlocking potential.Biotech startups face daunting challenges, but David Kiewlich, Founder and CEO of Tomorrow Biotech Corporation, has created a model that flips the odds. While most startups face a 90% failure rate, David's incubator, Badass Labs, boasts an astounding 95% success rate.The secret? David's incubator takes on time-consuming tasks and provides founders with the tools and support they need to focus on high-value activities. “We take what I call low-value, high-risk tasks off of the responsibility of these early founders,” David explained. By handling procurement, accounting, and regulatory compliance, the incubator saves startups time, money, and frustration.For example, David shared how the incubator's full-service procurement system saves companies more than 70 hours of work while also cutting costs. “Because it's a pooled spend model, it allows us to be one giant customer instead of many little ones,” he said. This approach not only improves efficiency but also doubles the runway for many startups.David's focus goes beyond logistics—he's also deeply invested in coaching founders to grow. He emphasized the importance of coachability, saying, “If they are open to guidance and comfortable with being vulnerable, they'll grow.” This hands-on support ensures founders avoid rookie mistakes, expand their skill sets, and present their companies as professional and investor-ready.The work being done at Badass Labs and Tomorrow Biotech isn't just about improving success rates—it's about saving lives. By accelerating the development of biotech innovations, David's incubator is paving the way for groundbreaking ideas to reach the market faster.If you're inspired by David's approach and want to learn more about his incubator, visit badasslabs.org. With multiple locations across the U.S. and plans to expand, the program is open to biotech, climate tech, and other transformative startups. By helping founders focus on what matters most, David is proving that with the right support, startups can defy the odds and change the world.tl;dr:David Kiewlich's incubator flips the biotech startup success rate from 10% to 95% with unique support.The program removes tedious tasks, saving founders time and enabling them to focus on execution.Coachability is critical—David helps founders grow by fostering their confidence and guiding their development.David shared a superpower: unlocking potential by building up others and inspiring action.Tomorrow Biotech and Badass Labs accelerate innovation, empowering founders to bring life-saving ideas to market.How to Develop Unlocking Potential As a SuperpowerDavid Kiewlich's superpower is his ability to unlock the potential in others by fostering their confidence and helping them grow into their best selves. Reflecting on his life, David shared how he developed this skill early on, saying, “You become sort of focused on how you can lift up and protect everyone around you.” He uses this mindset to empower biotech founders, helping them become “superhumans” who think bigger, execute better, and achieve more.One inspiring story David shared highlights his superpower in action. Years ago, he organized a grassroots effort to rescue surplus food from wholesalers and deliver it to nonprofits across the San Francisco Bay Area. Over the course of a year, he single-handedly moved nearly 600,000 pounds of produce, ensuring it reached those in need instead of ending up in landfills. By showing what's possible, David inspired others to replicate his efforts, amplifying his impact.To develop this superpower, David suggests:Focus on building up others rather than seeking credit for yourself.Encourage people by expressing belief in their abilities.Help others see what's possible by setting an example.Support people in a way that allows them to focus on their strengths.By following David's example and advice, you can make unlocking potential a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileDavid Kiewlich (he/him):Founder and CEO, Tomorrow Biotech CorporationAbout Tomorrow Biotech Corporation: Tomorrow Biotech Corporation consists of an accelerator fund, an early stage fund and includes the Bay Area Disruptor and Startup Support Labs (BADASS Labs) a 501c3, non-profit series of biotech incubators. While the funds are new, the incubator has been in operation for 6 years, supporting dozens of pre-seed through series B (and beyond) companies. With a track record of 50 of 55 company successes for members of the incubator, this ecosystem has a uniquely successful approach to founder support, which has substantially changed the concept and expectations for early stage incubators. BADASS Labs is more than a 501c3, non-profit biotech incubator that rents lab space to small businesses. It is a strategic ally that empowers biotech entrepreneurs to achieve their full potential. By offering a comprehensive suite of services, such as purchasing, waste management, operations and even health insurance plans for its members, BADASS Labs enables its clients to focus on their core competencies and substantially reduce their operational costs. BADASS Labs bridges the gap between research and commercialization, by facilitating novel technologies from academic, national lab or self-generated sources into viable products that can enhance the domestic supply chain and generate regional employment. While we can incubate companies at any stage, we have a particular focus on the earlier side, from Pre-Seed through Series B stages.Website: badasslabs.org, TomorrowBiotech.com, MissionBoosterProcurement.comBiographical Information: Dr. David Kiewlich (Ph.D. in Cell and Developmental Biology) is a serial founder and entrepreneur in biotech. With over 35 years' experience working for industry, as well as 6 startups of his own (in Oncology, Cell Based Therapies and Synthetic Biology), his background is excellently aligned with the needs and struggles of pre-commercialization startups. He founded and runs Tomorrow Biotech, which includes the Bay Area Disruptor and Startup Support Labs (BADASS Labs) a 501c3, non-profit series of biotech incubators, which has supported dozens of pre-seed through series B (and beyond) companies, as well as a startup and early-stage fund. In addition to Tomorrow Biotech, David is also the CSO of a cell based therapy company, focused on autoimmune disease, advisor for several biotech startups and frequent public speaker advocating for increased sustainability and greater Diversity, Equity and Inclusion (DEI) in the sciences.LinkedIn Profile: linkedin.com/in/davidkiewlichSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, and Rancho Affordable Housing (Proactive). Learn more about advertising with us here to help us Power Up October.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on October 28, 2025, at 1:30 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, November 19, 2025, at 12:00 PM Eastern — Devin Thorpe, CEO and Founder of The Super Crowd, Inc., will lead a session on “Investing with a Self-Directed IRA.” In this session, Devin will explain how investors can use self-directed IRAs to participate in regulated investment crowdfunding while managing taxes and optimizing returns. He'll break down when this strategy makes sense, how to choose the right custodian, and what fees, rules, and risks to watch for. With his trademark clarity and real-world experience, Devin will help you understand how to balance simplicity with smart tax planning—so you can invest confidently, align your portfolio with your values, and make your money work harder for both impact and income.SuperGreen Live, January 22–24, 2026, livestreaming globally. Organized by Green2Gold and The Super Crowd, Inc., this three-day event will spotlight the intersection of impact crowdfunding, sustainable innovation, and climate solutions. Featuring expert-led panels, interactive workshops, and live pitch sessions, SuperGreen Live brings together entrepreneurs, investors, policymakers, and activists to explore how capital and climate action can work hand in hand. With global livestreaming, VIP networking opportunities, and exclusive content, this event will empower participants to turn bold ideas into real impact. Don't miss your chance to join tens of thousands of changemakers at the largest virtual sustainability event of the year.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Impact Accelerator Summit is a live, in-person event taking place in Austin, Texas, from October 23–25, 2025. This exclusive gathering brings together 100 heart-centered, conscious entrepreneurs generating $1M+ in revenue with 20–30 family offices and venture funds actively seeking to invest in world-changing businesses. Referred by Michael Dash, participants can expect an inspiring, high-impact experience focused on capital connection, growth, and global impact.If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

Bioengineer Michael Fischbach studies alternative vaccine delivery methods, like self-administered creams with no needles, health professionals, or side effects. He teases a day when vaccines that don't make you feel bad come in the mail in ketchup-style packets. Such innovations would greatly improve vaccine uptake, especially in developing countries, and speed global response to novel viruses. It would change how we think about vaccines, Fischbach tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Michael FischbachConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Michael Fischbach, a professor of bioengineering at Stanford University.(00:04:24) Cream-Based VaccinesThe discovery that revealed the skin's ability to spark systemic immunity.(00:07:36) Engineering ImmunityModifying staph epidermidis to carry antigens and test immune response.(00:09:38) Tumor RegressionHow engineered bacteria triggered tumor-killing immunity in mice.(00:12:53) Antibody DiscoveryEvidence that skin exposure can generate long-lasting antibodies.(00:17:02) Antibody Response in HumansWhether humans show antibody responses to their own skin bacteria.(00:18:42) Turning Bacteria into VaccinesEmbedding harmless pathogen fragments into bacterial surface proteins.(00:20:55) Immunity Without ShotsHow mice achieved vaccine-level immunity through topical application.(00:24:00) Reimagining Vaccine DeliveryThe potential for self-applied, needle-free, and multiplexed vaccines.(00:26:50) Mechanism Behind Skin ImmunityHow skin immune cells may constantly sample microbes for defence.(00:28:14) Next Steps in DevelopmentThe path toward testing safety, dosage, and delivery in higher models.(00:29:57) Choosing Vaccine TargetsViruses and diseases that could be targets for early skin-based vaccines.(00:31:11) Safety and ReversibilityEnsuring safety with reversible bacteria and limited trial participants.(00:33:04) Transitioning to BiotechTransitioning research from Stanford to large-scale biotech development.(00:34:31) Future In a MinuteRapidfire Q&A: creative science, vaccine innovation, and biology's future.(00:36:56) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Serial entrepreneur Michael Heltzen, CEO of Exozymes, reveals how his NASDAQ-listed company is "liberating enzymes from cells" to create a new generation of chemical manufacturing. Instead of using living cells as factories, Exozymes isolates enzymatic pathways to work as pure chemistry—achieving engineering-level control previously deemed impossible in conventional synthetic biology. Michael discusses Exozymes' AI-powered enzyme evolution, six-week development timelines, bold IPO strategy during biotech's funding winter, and applications in pharmaceuticals like NCT for liver disease. This is synthetic biology's next chapter: sustainable, scalable enzyme-based manufacturing that could replace both petrochemicals and natural harvesting. Make sure to check out eXoZymes' website: https://exozymes.com/ Follow our Instagram @insidebiotech for updates about episodes and upcoming guests! To learn more about BCLA's events and consulting visit our website.Follow BCLA on LinkedIn

Ben Lamm is CEO and Co-founder of Colossal Biosciences, the world's first de-extinction company. Colossal has raised more than $400 million at a valuation north of $10 billion to bring back extinct species using synthetic biology and genetic engineering. Just this year, the company unveiled the first dire wolves born in 12,000 years, created woolly mice with mammoth-like fur, and remains on track to see woolly mammoth calves by 2028.This conversation explores Colossal's end-to-end platform approach, from ancient DNA recovery to multiplex genome editing, and why Ben sees de-extinction not just as science fiction come true but as a venture-scale business that spins out companies, partners with governments, and raises profound ethical questions. We cover polarizing public reactions, the conservation potential of rewilding keystone species, and how synthetic biology and AI are accelerating breakthroughs once thought impossible.Episode recorded on Aug 20, 2025 (Published on Sept 23, 2025)In this episode, we cover: [04:14] An overview of Colossal[05:47] The company's dire wolf pups debut[10:51] Reasons behind de-extinction[11:49] Mammoth vs. thylacine vs. dodo challenges[18:40] How Ben co-founded a bioscience company[20:56] George Church and Colossal's origin story[22:40] The “why” behind bringing back the mammoth[27:42] Colossal's biodiversity credit carbon model[28:43] Trade-offs between rewilding existing species vs extinct[31:35] Colossal's multifaceted business model[33:58] The company's plastic-eating enzyme spinout[37:57] Colossal's unique speed of R&D[40:38] The Colossal Foundation[42:29] Ben's pov on our moral obligation to transparency Enjoyed this episode? Please leave us a review! Share feedback or suggest future topics and guests at info@mcj.vc.Connect with MCJ:Cody Simms on LinkedInVisit mcj.vcSubscribe to the MCJ Newsletter*Editing and post-production work for this episode was provided by The Podcast Consultant

In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio, Alex discusses his journey from studying biochemistry at UCL to founding a company that develops software tools for streamlining biopharmaceutical workflows.The conversation dives into the impact of AI and language models on the biotech industry, addressing inefficiencies in drug development, and exploring the potential of synthetic biology and personalized medicine. The discussion also touches on the future of drug discovery, China's role in biotech, and the challenges of understanding neuroscience and consciousness. Don't miss this insightful discussion on the future of biopharma innovation! 00:00 Welcome to Idea Collider00:04 Introducing Alex Telford01:59 Alex's Journey from UCL to Convoke Bio05:29 The Mission and Work of Convoke Bio07:57 Challenges in Pharma Decision Making14:05 The Role of AI in Pharma18:26 Knowledge Management and AI27:58 Staying Updated in the Fast-Moving AI Field30:25 AI's Impact on Industry Economics31:38 AI in Clinical Trials and Drug Development35:56 China's Role in Drug Discovery39:24 Neuroscience and AI: Blurring the Lines46:05 Future Predictions in Pharma51:20 Addressing Cognitive Bias in Pharma53:13 Concluding Thoughts and Future Directions Keep up with Alex Telford;LinkedIn: https://www.linkedin.com/in/alexander-telford/Website: atelfo.github.ioX: https://twitter.com/atelfoSubstack: atelfo.substack.com Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this bonus episode, we're sharing a conversation from our recent CEO Retreat in Puglia, Italy. The theme for the event was “Navigating new global realities.” Dr. Tiffany Vora shared new developments in synthetic biology and explored how it will transform industries far beyond healthcare. Listen for her take on questions like:   (2:31) What is synthetic biology, and what are the major advancements we should be tracking?  (11:47) How is our concept of human longevity going to change? (15:31) What should business leaders know about synthetic biology and its impact on business?   Reimagining the Future is produced by the Global Business Policy Council at Kearney, a think tank that deciphers sweeping geopolitical, economic, social, and technological changes and their effects on the global business environment. Learn more at kearney.com/gbpc.  

What is the origin of life in the universe? Neil deGrasse Tyson and Matt Kirshen explore how life got its start, the Miller-Urey experiment, and synthetic biology with molecular biologist Kerstin Göpfrich. Could the first alien life we find be the one we make? NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free here: https://startalkmedia.com/show/building-life-from-scratch-with-kerstin-gopfrich/Thanks to our Patrons Kory Thompson, Scott Brooks, Evelyn ZB, Ken Robertson, Richard Iserman, JenFran, Adam Peters, roccie hill, Linux Diner, Steve Jaeger, Devona Johnson, Aaron Cortese, Jennifer Hoying, Brian Howard, kuwar Ahluwalia, Tal Kennedy, Amanda Echon, Michael McCarron, George Katsoufis, Martin BElan, sebby randazzo, Doug, Eval, Nate Amsden, Preston Kersey, Brian, Larbi, Aaron N., Ericka Nightshade, Alisha Okoroafo, karla, Daniel Mekonnen, James J.C. Kelly, MM, Josue Montanez, Stephen Addy, Fox Riley, Caleb Lillard, Louis-Gabriel Thibault, Wendy Kleeb, Jakob Linderoth, Aura, Mary, Mike D'Agostino, Julia Donehew, Jorge, Daniel Tersigni, Lindsay M., Jay Dakota Nance, and Goose for supporting us this week. Subscribe to SiriusXM Podcasts+ to listen to new episodes of StarTalk Radio ad-free and a whole week early.Start a free trial now on Apple Podcasts or by visiting siriusxm.com/podcastsplus.

Recently, a group of world-leading scientists called for a halt on research to create ‘mirror life' microbes amid concerns that the synthetic organisms would present an ‘unprecedented risk' to life on Earth. Ian Sample tells Madeleine Finlay about why this work initially seemed exciting for scientists and what the risks of it continuing could be. Kate Adamala, assistant professor of genetics, cell biology and development at the University of Minnesota, describes what made her change her mind about pursuing her own research on mirror cells. Help support our independent journalism at theguardian.com/sciencepod

Chemical engineer Beth Sattely studies the intricate chemistry of plant life. Plants are more than food, she says: They are living chemical factories churning out molecules that help plants do everything from adapting to climate change to fighting infections – or even producing valuable new cancer drugs. Lately, Sattely's lab is working on ways to make crops more resilient to engineer more sustainable foods and environments. Some of our most exciting technologies already exist in nature, we just have to find them, Sattely tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Elizabeth SattelyConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Beth Sattely, a professor of chemical engineering at Stanford University.(00:03:10) Path to Plant MetabolismHow chemistry and gardening led to a career in plant science.(00:03:54) Environmental and Human HealthUsing plants to improve both the planet and people's well-being.(00:04:53) Engineering Climate-Resilient CropsMaking crops more sustainable and nutritious amid global change.(00:05:58) Old vs. New Crop EngineeringComparing traditional breeding with modern molecular tools.(00:08:04) Industry and Long-Term Food SecurityThe gap between short-term market goals and long-term environmental needs.(00:09:13) Tomato ChemistryTomatoes reveal how plants produce protective molecules under stress.(00:12:26) Plant “Vaccines” and Immune SignalingHow plants communicate threats internally and mount chemical defenses.(00:14:14) Citrus Greening and LimonoidsThe potential role of limonoid research on citrus greening.(00:16:59) Plants Making MedicineHow plants like Yew trees naturally produce cancer drugs like Taxol.(00:21:19) Diet as Preventative MedicineIdentifying plant molecules to understand their preventative health effects. (00:24:36) Food Allergies and Plant ChemistryWhy the immune system tolerates some foods and rejects others.(00:26:42) Understanding Tolerance in ImmunityPossibility of reintroducing tolerance through partial molecular exposure.(00:28:02) Engineering Healthier PlantsPotential for designing plants to enhance micronutrient content.(00:29:04) Training the Next GenerationBeth celebrates her students' role in shaping a sustainable future.(00:30:39) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

FOLLOW RICHARD Website: https://www.strangeplanet.ca YouTube: @strangeplanetradio Instagram: @richardsyrettstrangeplanet   EP. #1225 REM Clones & Ritual Arenas: The Elite's Sinister Doppelgänger Plot In this chilling episode of Strange Planet, Richard delves into the sinister world of human cloning with researcher Elana Freeland. Exploring her editorial work on 21st Century MK-Ultra Slave, they dissect Ron Alan's harrowing tale of trauma-based mind control fused with cybernetic implants and spiritual hijacking. The discussion turns to Donald Marshall's shocking claims of elite-run cloning centers in Deep Underground Military Bases, where synthetic doubles are exploited. From scalar waves to soul fragmentation, this episode probes whether human identity is a programmable pawn in a nefarious subterranean agenda. GUEST: Elana Freeland is a titan of truth, wielding decades of relentless research to expose the hidden machinations of global control. A scholar of geoengineering, transhumanism, and consciousness militarization, she authored the seminal trilogy: Chemtrails, HAARP, and the Full Spectrum Dominance of Planet Earth, Under an Ionized Sky, and Geoengineered Transhumanism. As editor of 21st Century MK-Ultra Slave, Freeland amplifies survivor voices, weaving their testimonies into her unflinching analysis of electromagnetic warfare and synthetic biology. With a fearless pen and metaphysical lens, she unveils the elite's silent weapons, challenging humanity to reclaim its sovereignty in a technocratic age.  WEBSITE: https://www.patreon.com/ElanaFreeland   BOOKS: Chemtrails, HAARP and the Full Spectrum Dominance of Planet Earth Under an Ionized Sky: From Chemtrails to Space Fence Lockdown Geoengineered Transhumanism The Geoengineered Transhuman: The Hidden Technologies of HAARP, Chemtrails, 5G/6G, Nanotechnology, Synthetic Biology, and the Scientific Effort to Transform Humanity  SUPPORT OUR SPONSORS!!! ⁠BUTCHERBOX⁠ ButcherBox delivers better meat and seafood straight to your door – including 100% grass-fed beef,free-range organic chicken, pork raised crate-free, and wild-caught seafood. Right now, ButcherBox is offering our listeners $20 off their first box and free protein for a year. Go to ⁠ButcherBox.com/strange⁠ to get this limited time offer and free shipping always. Don't forget to use our link so they know we sent you.   HIMS - Making Healthy and Happy Easy to Achieve Sexual Health, Hair Loss, Mental Health, Weight Management START YOUR FREE ONLINE VISIT TODAY - HIMS dot com slash STRANGE https://www.HIMS.com/strange ⁠⁠RingBoost⁠⁠ The largest provider of custom phone numbers since 2003 ⁠⁠https://www.ringboost.com⁠⁠ If you're ready to sound like the business people want to call, head over to ⁠⁠https://www.ringboost.com⁠⁠ and use promo code STRANGE for an exclusive discount. QUINCE BEDDING Cool, Relaxed Bedding. Woven from 100% European flax linen. Visit QUINCE BEDDING to get free shipping on your order and 365-day returns. BECOME A PREMIUM SUBSCRIBER!!!  https://strangeplanet.supportingcast.fm Three monthly subscriptions to choose from.  Commercial Free Listening, Bonus  Episodes and a Subscription to my monthly newsletter, InnerSanctum.  Visit https://strangeplanet.supportingcast.fm Use the discount code "Planet" to receive one month off the first subscription.  We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/

In this inspiring episode of the BioBuilder Podcast, Dev and Joshua, co-founders of the startup AIVON, take listeners through their personal journeys of curiosity, innovation, and social impact. The conversation weaves through their formative experiences with science and technology, their time in the BioBuilderClub, and their ambitious venture into the world of AI-powered healthcare. Origins of Scientific CuriosityDev recounts how growing up in a science-loving household, with parents and an aunt deeply engaged in the subject, laid the groundwork for his fascination. From tinkering with technology alongside his dad to wondering about disease mechanisms, he developed an early love for biology and engineering. This curiosity eventually led him to Alliance Academy, where he joined the BioBuilder Club, a decision that would define much of his scientific identity. The BioBuilder ExperienceAs part of the BioBuilder program, Dev and his team designed a sustainable biofiltration system that uses genetically engineered bacteria (E. coli, Bacillus subtilis, and Pseudomonas putida) to remove heavy metals from water. The bacteria were enhanced with plasmids encoding metal-detoxifying enzymes and embedded in a biochar-based medium for stability and efficiency. Their modular, scalable filter design bridged biology and engineering in a way that was both educational and impactful. Dev credits BioBuilder for teaching him adaptability, technical rigor, and how to bring abstract ideas to life. Collaboration & DiscoveryThe episode explores how Dev collaborated with peers to develop their project, noting “aha!” moments when the science began to click. The iterative nature of their work, coupled with expert guidance from mentors like Dr. Grace Vezeau and Ms. Caroline Matarrese, helped deepen their understanding of real-world science. Soft skills like communication and teamwork were just as vital as technical prowess, a lesson Dev carries into his startup journey into career paths, possibly through an MD-PhD program.Building AIVON and MedisenseShifting to the theme of innovation, Dev and Joshua introduce their startup AIVON, based in Atlanta. Their flagship product, MediSense, is an AI-powered diagnostic platform that allows users to input symptoms and receive real-time health assessments. The idea was born from the intersection of their scientific training and the urgent need for accessible, intelligent healthcare tools.They share how conversations with patients, doctors, and mentors shaped MediSense's design and functionality, emphasizing the importance of user feedback in product development. Their goal is to make fast, affordable, and intelligent diagnostics available to everyone, especially in underserved areas. Despite challenges—from building the tech to managing startup logistics—they remain focused on scaling the product and seeking potential partnerships with hospitals and schools.Learn more about BioBuilder's programs for students, educators, and industry professionals here

My guest today is someone whose work has shaped the very code of modern biology, and whose vision continues to ripple across fields as vast as genomics, synthetic biology, age reversal, and artificial intelligence.Dr. George Church is a a true pioneer, Professor of Genetics at Harvard Medical School,a molecular engineer, chemist and serial entrepreneur as the co-founder of more than 50 biotech companies. He has helped invent many of the technologies that now define the genomic era, from CRISPR optimization to DNA data storage, and he was one of the first humans to ever publicly share his full genome and medical history.In this conversation, we explore the edge where science meets spirit.We talk about synthetic biology as a modern myth, DNA as a vessel of intelligence, and what it means to engineer life with intention. We dive into radical transparency, longevity research, AI collaboration, and the philosophical gravity of rewriting the arc of aging.This episode is not just about technology. It is about becoming.It is about asking: What does it mean to choose our evolution, consciously, ethically, and with awe.Episode highlights:00:04:30 – Sleep states and engineered serendipity: tapping creativity through unconscious rhythms00:06:30 – Synthetic biology as a modern myth: Promethean fire and the sacred aesthetic of science00:08:30 – DNA as memory, medium, and myth: encoding images in bacterial genomes00:10:00 – Is DNA a vessel of intelligence beyond biology?00:13:30 – Preserving culture in encoded DNA: who might decode it in the far future?00:16:00 – Are we alone in the universe? Dr. Church's speculative yet grounded view00:18:30 – What should we preserve for the next million years? The humility of legacy00:21:00 – DNA as sacred text: what it teaches us about identity, ancestry, and consciousness00:24:00 – Radical transparency: the Personal Genome Project and sharing his own genome00:29:00 – Rethinking consent, privacy, and research ethics in human genomics00:32:00 – From printing press to gene sequencers: the dawn of programmable biology00:33:30 – From slowing aging to redesigning it: reprogramming human cells and organs00:36:00 – How smarter gene, cell, and organ therapies could surpass pharmaceuticals00:40:00 – Personalized vs. generic medicine: the case for affordable global health00:43:30 – Aging as a treatable condition: tackling multiple pathways at once00:46:30 – Ethical and spiritual questions at the threshold of biological reinvention00:49:00 – The risks of artificial general intelligence vs. the promise of scientific AI00:52:30 – Why narrow scientific AI (like protein design) offers real-world breakthroughs00:54:30 – Will synthetic intelligence ever hold ethical responsibility?00:55:00 – Final reflections: safety, accessibility, and helping humanity fulfill its potentialResources mentioned:WebsitesWyss Institute: https://wyss.harvard.edu/team/core-faculty/george-church/Harvard Department of Genetics: https://icgd.bwh.harvard.edu/team/george-churchBiophysics at Harvard: https://biophysics.fas.harvard.edu/people/george-m-churchChurch Lab:

What if we could rewrite the code of life—just like editing a Word doc?Gene-editing pioneer David Liu takes us behind the scenes of the revolutionary tools transforming medicine. He's the Harvard scientist who invented base editing—a breakthrough that lets scientists fix a single DNA letter to correct genetic disease at its root.This is science fiction come to life—and it's happening now. He edits DNA like we edit text. Come meet the man who's changing lives, one letter at a time. 

Buy the book - https://tinyurl.com/5a8x8kcmThe Geoengineered Transhuman: The Hidden Technologies of HAARP, Chemtrails, 5G/6G, Nanotechnology, Synthetic Biology, and the Scientific Effort to Transform HumanityBuilding on decades of research, Elana Freeland offers a comprehensive exposé of the transhumanist agenda—the transformation of humanity into a slave class by means of biotechnology, genetic engineering, molecular nanotechnology, and artificial intelligence. She reveals that weather control is already a global reality thanks to the aerosol chemtrails that maintain the ionized atmosphere needed for a myriad of military and civilian wireless operations. The air we breathe, the soil we grow our food in, and the water we drink have all been altered away from Nature and toward a synthetic "metaverse." Meanwhile, Big Pharma injects nano-sized hardware and software in vivo that activate a transhumanist brain-computer interface with AI. The author also examines the public-private partnerships behind transhumanism and reveals the reality of the secret space program and the planetary "smart grid" of 5G/6G.Sheep Farm www.sheepfarm.co.ukhttps://www.youtube.com/@sheepfarmstudios2921/videoshttps://www.podomatic.com/podcasts/sheepfarmstudioshttps://rumble.com/user/SheepFarmStudiohttps://odysee.com/@sheepfarmstudios:fDom's Health Bunker Supplements www.shop.healthbunker.co.ukUse discount Codes HB-SF10OFF for NEW Liposomal Vitamin C & HB-SF25OFF for all HB other Products. But discount codes can be used at checkout.*Discount Codes only available on Health Bunker Products*Health Bunker Clinic www.healthbunker.co.ukChris's Gaping Gobs – Etsy UK

#ControlTheFoodControlThePeople #4thIndustrialRevolution #Jeremiah6:16 Bards Nation Health Store: https://www.bardsnationhealth.com BIRCH GOLD Infokit:  >>>Text BARDS to 989898 MYPillow promo code: BARDS Go to https://www.mypillow.com/bards and use the promo code BARDS or... Call 1-800-975-2939.  Support Pete Chambers Team: https://theremnantministrytx.org WNC Mountain Ops: https://baldguybrew.com Founders Bible 20% discount code: BARDS >>> https://thefoundersbible.com/#ordernow Mission Darkness Faraday Bags and RF Shielding. Promo code BARDS: Click here EMPShield protect your vehicles and home. Promo code BARDS: Click here EMF Solutions to keep your home safe: https://www.emfsol.com/?aff=bards Treadlite Broadforks...best garden tool EVER. Promo code BARDS: Click here DONATE: https://store.bardsnation.com/donate/ Mailing Address: Xpedition Cafe Attn. Scott Kesterson 591 E Central Ave, #740 Sutherlin, OR  97479

Can AI help us model biology down to the molecular level? Neil deGrasse Tyson, Chuck Nice, and Gary O'Reilly learn about Nobel-prize-winning Alphafold, the protein folding problem, and how solving it could end disease with AI researcher, Max Jaderberg. NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free here: https://startalkmedia.com/show/curing-all-disease-with-ai-with-max-jaderberg/Thanks to our Patrons Riley r, pesketti, Lindsay Vanlerberg, Andreas, Silvia Valentine, Brazen Rigsby, Marc, Lyda Swanston, Kevin Henry, Roberto Reyes, Cadexn, Cassandra Shanklin, Stan Adamson, Will Slade, Zach VanderGraaff, Tom Spalango, Laticia Edmonds, jason scott, Jigar Gada, Robert Jensen, Matt D., TOL, Thomas McDaniel, Sr., Ryan Ramsey, truthmind, Aaron TInker, George Assaf, Dante Ruzinok, Jonathan Ford, Just Ernst, David Eli Janes, Tamil, Sarah, Earnest Lee, Craig Hanson, Rob, Be Love, Brandon Wilson, TJ Kellysawyer, Bodhi Animations, Dave P., Christina Williams, Ivaylo Vartigorov, Roy Mitsuoka (@surflightroy), John Brendel, Moises Zorrilla, deborah shaw, Jim Muoio, Tahj Ward, Phil, Alex, Brian D. Smith, Nate Barmore, John J Lopez, Raphael Velazquez Cruz, Catboi Air, Jelly Mint, Audie Cruz for supporting us this week. Subscribe to SiriusXM Podcasts+ to listen to new episodes of StarTalk Radio ad-free and a whole week early.Start a free trial now on Apple Podcasts or by visiting siriusxm.com/podcastsplus.

Join Mike Jaco in another enlightening episode of Unleashing Intuition Secrets as he hosts the Healing for the Ages team: Dr. Ardis, Dr. Group, and Dr. Ealy. Despite the absence of Dr. Schmidt, the discussion delves deep into practical health advice and alarming revelations about everyday products that could be impacting your health.   Discover how environmental toxins contribute to common diseases, the truth about 'forever chemicals' in household items, and insights into the transhumanism agenda. Highlighting the disturbing chemicals in toilet paper and the critical importance of a healthy living environment, this episode aims to educate, inspire, and provide hope.   Learn how to make your home and yourself healthier with actionable advice from top holistic health experts.  

We love to hear from our listeners. Send us a message.Host Erin Harris talks to Generate:Biomedicines' EVP of R&D, Dr. Alex Snyder about the convergence of AI, machine learning (ML), and synthetic biology in the development of next-generation therapies. They cover how AI is transforming drug discovery by enabling the rapid design and optimization of therapeutic candidates, particularly in complex fields like immuno-oncology and cell therapy. Dr. Snyder shares how that in the context of CAR-T therapies, AI-driven approaches are used to design and refine each component of the CAR construct. And, Dr. Snyder sets the stage for a broader conversation about how the integration of AI and synthetic biology is not only accelerating drug development timelines but also expanding the realm of what's possible in cell-based therapeutics.Subscribe to the podcast!Apple | Spotify | YouTube

In this episode of Data in Biotech, host Ross Katz speaks with Patrick Torbey, CEO and Co-Founder of Neoplants, about using genetic engineering and microbiome innovation to tackle indoor air pollution. Patrick explains how Neoplants is turning everyday houseplants into powerful air purifiers using synthetic biology, offering insights into VOC degradation, enzyme pathways, and data-driven R&D. ​​What You'll Learn in This Episode: How genetically modified plants and microbiomes can reduce indoor air pollution by targeting VOCs like formaldehyde and benzeneThe scientific and engineering challenges of modifying indoor plants at the genomic levelWhy data-driven testing and simulation are critical to optimizing plant function and user impactThe role of synthetic biology in creating sustainable, scalable biotech productsPatrick's vision for solving climate challenges through engineered plant ecosystems ​​Meet Our Guest: Patrick Torbey is the CEO and Co-Founder of Neoplants, a Paris-based biotech startup engineering plants to purify indoor air. With a PhD in genetic editing and deep expertise in synthetic biology, Patrick leads Neoplants in building functional, aesthetically unique, and sustainable plant systems for the future. About The Host: Ross Katz is the Principal Data Scientist at CorrDyn. He brings decades of experience across biotech, energy, and non-profit sectors, with a focus on building smarter data systems, machine learning pipelines, and actionable insights for complex industries. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyFind out more about NeoplantsConnect with Patrick Torbey on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!

De-extinction is no longer just science fiction. In this episode, we dive into the controversial concept of bringing back extinct species—specifically the dire wolf—using cutting-edge genetic engineering. Inspired by the headline-grabbing efforts to resurrect woolly mammoths, scientists are now exploring how DNA from ancient canids could be used to reintroduce this Ice Age predator into modern ecosystems. Genetic engineering plays a central role in this story. From piecing together fragmented DNA to editing modern genomes, researchers face significant scientific, ethical, and ecological hurdles. What would it mean to bring back a dire wolf? Would the creature truly be a dire wolf—or a hybrid imitation? We explore what's possible, what's fantasy, and what responsibilities come with resurrecting the past. Follow a career in conservation: https://www.conservation-careers.com/online-training/ Use the code SUFB to get 33% off courses and the careers program.   Do you want to join my Ocean Community? Sign Up for Updates on the process: www.speakupforblue.com/oceanapp   Sign up for our Newsletter: http://www.speakupforblue.com/newsletter   Facebook Group: https://bit.ly/3NmYvsI Connect with Speak Up For Blue: Website: https://bit.ly/3fOF3Wf Instagram: https://bit.ly/3rIaJSG TikTok: https://www.tiktok.com/@speakupforblue Twitter: https://bit.ly/3rHZxpc YouTube: www.speakupforblue.com/youtube  

AI isn't just growing—it's skyrocketing us into an unprecedented era of hyper-acceleration. Josh Kale joins us to explore how breakthroughs in intelligence, from protein sequencing and synthetic biology to autonomous transportation and energy abundance, are reshaping our world at dizzying speeds.  Prepare for a future that's closer than you think, where the cost of intelligence approaches zero and possibilities become boundless. ------

Recently, a group of world-leading scientists called for a halt on research to create ‘mirror life' microbes amid concerns that the synthetic organisms would present an ‘unprecedented risk' to life on Earth. Ian Sample tells Madeleine Finlay about why this work initially seemed exciting for scientists and what the risks of it continuing could be. And Kate Adamala, assistant professor of genetics, cell biology and development at the University of Minnesota, describes what made her change her mind about pursuing her own research on mirror cells. Help support our independent journalism at theguardian.com/sciencepod

Imagine a future in which Band-Aids talk to your cells, pacemakers are powered by light and your gut microbiome gets a tune-up—all thanks to tiny bioelectric devices. Sounds like sci-fi, right? Think again. Prof. Bozhi Tian of the University of Chicago is on the frontier of bioelectronics, building living machines that can heal, enhance and maybe even transform what it means to be human. In this episode, he explains his research lab's work and explores the thrilling, strange and sometimes unsettling world in which biology meets technology.

In this engaging conversation on the Crazy Wisdom podcast, Stewart Alsop talks with neurologist Brian Ahuja about his work in intraoperative neurophysiological monitoring, the intricate science of brainwave patterns, and the philosophical implications of advancing technology. From the practical applications of neuromonitoring in surgery to broader topics like transhumanism, informed consent, and the integration of technology in medicine, the discussion offers a thoughtful exploration of the intersections between science, ethics, and human progress. Brian shares his views on AI, the medical field's challenges, and the trade-offs inherent in technological advancement. To follow Brian's insights and updates, you can find him on Twitter at @BrianAhuja.Check out this GPT we trained on the conversation!Timestamps00:00 Introduction to the Crazy Wisdom Podcast00:21 Understanding Intraoperative Neurophysiological Monitoring00:59 Exploring Brainwaves: Alpha, Beta, Theta, and Gamma03:25 The Impact of Alcohol and Benzodiazepines on Sleep07:17 The Evolution of Remote Neurophysiological Monitoring09:19 Transhumanism and the Future of Human-Machine Integration16:34 Informed Consent in Medical Procedures18:46 The Intersection of Technology and Medicine24:37 Remote Medical Oversight25:59 Real-Time Monitoring Challenges28:00 The Business of Medicine29:41 Medical Legal Concerns32:10 Alternative Medical Practices36:22 Philosophy of Mind and AI43:47 Advancements in Medical Technology48:55 Conclusion and Contact InformationKey InsightsIntraoperative Neurological Monitoring: Brian Ahuja introduced the specialized field of intraoperative neurophysiological monitoring, which uses techniques like EEG and EMG to protect patients during surgeries by continuously tracking brain and nerve activity. This proactive measure reduces the risk of severe complications like paralysis, showcasing the critical intersection of technology and patient safety.Brainwave Categories and Their Significance: The conversation provided an overview of brainwave patterns—alpha, beta, theta, delta, and gamma—and their connections to various mental and physical states. For instance, alpha waves correspond to conscious relaxation, while theta waves are linked to deeper relaxation or meditative states. These insights help demystify the complex language of neurophysiology.Transhumanism and the Cyborg Argument: Ahuja argued that humans are already "cyborgs" in a functional sense, given our reliance on smartphones as extensions of our minds. This segued into a discussion about the philosophical and practical implications of transhumanism, such as brain-computer interfaces like Neuralink and their potential to reshape human capabilities and interactions.Challenges of Medical Technology Integration: The hype surrounding medical technology advancements, particularly AI and machine learning, was critically examined. Ahuja highlighted concerns over inflated claims, such as AI outperforming human doctors, and stressed the need for grounded, evidence-based integration of these tools into healthcare.Philosophy of Mind and Consciousness: A recurring theme was the nature of consciousness and its central role in both neurology and AI research. The unresolved "hard problem of consciousness" raises ethical and philosophical questions about the implications of mimicking or enhancing human cognition through technology.Trade-offs in Technological Progress: Ahuja emphasized that no technological advancement is without trade-offs. While tools like CRISPR and mRNA therapies hold transformative potential, they come with risks like unintended consequences, such as horizontal gene transfer, and the ethical dilemmas of their application.Human Element in Medicine: The conversation underscored the importance of human connection in medical practice, particularly in neurology, where patients often face chronic and emotionally taxing conditions. Ahuja's reflections on the pitfalls of bureaucracy, private equity in healthcare, and the overemphasis on defensive medicine highlighted the critical need to prioritize patient-centered care in an increasingly technological and administrative landscape.

Part 2 of 4: My guest today is Rafael Rosengarten, CEO and Co-Founder of Genialis, the RNA biomarker company. Genialis is reimagining biomarkers for every target, drug, and patient using a combination of precision oncology, RNA, and AI. Rafael, a biomedical research veteran, combines academic excellence with industry innovation. A Dartmouth graduate with a Yale doctorate, he conducted postdoctoral research at Lawrence Berkeley National Laboratory, where he co-invented the j5 DNA assembly tool. As co-founder of the Alliance for AI in Healthcare, he advocates for responsible AI integration in medicine, drawing from his extensive background in evolution, immunology, bioengineering, and genetics.

"Unlocking the Mysteries of Mind and Matter: Professor Michael Levin's Quantum Insights on The Dov Baron Show" . Introduction: In this episode of "The Dov Baron Show," we're once again stepping into a riveting exploration of the boundaries where science meets consciousness. Join us as Professor Michael Levin, a distinguished figure at the forefront of developmental biophysics and synthetic biology, unveils groundbreaking research that could revolutionize our understanding of life itself. . We'll pull back the curtain on regenerative medicine and examine the synthetic biology of novel life forms. Professor Levin's work at Tufts University and Harvard's Weiss Institute challenges our conventional views on biology and technology. . Prepare to expand your perception of reality in this mind-bending journey into quantum effects. Join us on "The Dov Baron Show" as we unravel these profound insights with Professor Michael Levin, challenging what we know about life, intelligence, and the very fabric of reality. . Key Learnings: The Essence of Curiosity: Understand why curiosity is not just beneficial but essential in today's complex world, helping us navigate immense social and scientific challenges.   Science vs. Dogma: Explore the tension between established scientific paradigies and the openness required for innovative breakthroughs. . The Inertia of Ideas: Learn about the systemic inertia that often prevents new scientific ideas from being accepted and how it compares to religious dogmatism. . Redefining Intelligence: Discover a broader, more inclusive definition of intelligence that goes beyond human capacities and encompasses a wide range of life forms. . Problem Solving Across Species: Examine how different organisms and systems solve problems and adapt to their environments, redefining our concepts of intelligence. . The Role of Autonomy in Intelligence: Delve into how autonomy and problem-solving capabilities contribute to our understanding of intelligence across various domains. . Scientific Methodology in Questioning Beliefs: Learn the importance of establishing clear criteria for changing one's scientific or personal viewpoints, promoting a more dynamic and flexible approach to knowledge. . Dov Baron's brand new course has just been released on coursifyx.com/belonging ------------- Titled: "CREATING A CULTURE OF BELONGING." The course is divided into eight sections, each of which will guide you through exactly how to create a culture of belonging. . Because: CREATING A CULTURE OF BELONGING MAXIMIZES PERSONAL AND CORPORATE SUCCESS. Get Ready to strap on the tanks and Dive Deep into, What it Takes to Create a Culture of Belonging in your organization! Curious to know more? coursifyx.com/belonging .  "Those Who Control Meaning for The Tribe, Also Control The Movement of That Tribe" #leadership #leadershipdevelopment #emotionsourcecode #neuroscience #emotional #meaning #emotional #logic #culture #curiosity #humanbehavior

What is life? Neil deGrasse Tyson and co-host Chuck Nice tackle assembly theory, artificial life, and the origin of lifeforms in the universe as we revise the definition of life with astrobiologist and theoretical physicist Sara Imari Walker.NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free here: https://startalkmedia.com/show/the-origins-of-life-with-sara-imari-walker/Thanks to our Patrons Bill Williamson, Amanda, Charles Waggoner, Jason Wiatr, Don Lane, Biren Amin, Jean C Roy, david accetta, STAHLGEIST, joshua george, Danny, daniel oliveira, Matthew Szwajda, Gabe Magallanes, Mike Jespersen, Elias, and Jon O for supporting us this week. Subscribe to SiriusXM Podcasts+ on Apple Podcasts to listen to new episodes ad-free and a whole week early.

This week, we're diving deep into some really clever and cutting-edge tech for Martian habitats... made from fungus! Dr. Lynn Rothschild of the NASA Ames Research Center has been working for years on how mushroom mycelia might be utilized as a habitat-building resource. It's quite fascinating--the organic material can be used to make bricks, to create shaped structures, and even to create an "astropharmacy" to supply certain compounds needed by the crew of a Mars excursion! And it is sufficiently enticing that NASA's NIAC innovation program has given her no less than five grants (which are not easy to get!) to study the possibilities. Join us for this really engaging and blue-sky conversation! Headlines: • ISS has been experiencing a slow air leak, increasing from 0.2 pounds per day to 3.7 pounds per day, causing concern for NASA's Office of the Inspector General • Jupiter's Great Red Spot has been shrinking and "pulsing" over time, as observed by the Hubble Space Telescope, with scientists predicting it will eventually stabilize as a smaller, circular storm • A rare G4-class solar storm triggered widespread auroras visible at much lower latitudes than usual, with NOAA issuing warnings to protect power grids and communication systems Main Topic - Living in Martian Mushrooms: • Dr. Rothschild explains synthetic biology as creating something new with biology, either by altering existing organisms or creating new ones from scratch • The concept of using fungal mycelium for off-world habitats originated from a student project to create a biodegradable drone body • Mycotecture involves growing habitats and structures using mycelium, which can bind various materials like sand, regolith simulant, and wood chips • The properties of mycelium-based materials can be tuned by adjusting the substrate and post-processing, ranging from styrofoam-like to hardwood-like consistencies • Dr. Rothschild's vision for a stable off-world habitat includes using cyanobacteria to process atmospheric gases and minerals, which would then feed the fungi used in construction • Cross-contamination concerns on Mars are addressed, with the lack of liquid water on the surface making it unlikely for introduced organisms to thrive • Additional applications of mycelium-based technology include biomining, water filtration, and even food production • Dr. Rothschild also discusses the Astro Pharmacy project, which aims to develop an on-demand drug production system for astronauts • While these technologies have significant potential for Earth-based applications, developing them for space allows for more freedom to explore revolutionary ideas without existing infrastructure constraints Hosts: Rod Pyle and Tariq Malik Guest: Dr. Lynn Rothschild Download or subscribe to this show at https://twit.tv/shows/this-week-in-space. Get episodes ad-free with Club TWiT at https://twit.tv/clubtwit Sponsors: uscloud.com veeam.com

You've heard of fruit leather, but what about making leather from fruit? Or more precisely, feeding fruit waste like mango pulp to bacteria which then convert those sugars into a leather-like material that can be useful for all types of purposes? That's exactly what Polybion, a startup in Central Mexico, is doing. Co-founded in 2015 by two brothers with a passion for using biology to save humanity from ourselves—as CEO Axel Gómez-Ortigoza puts it—Polybion has pioneered methods of turning the fruit industry's trash into what they hope will be their treasure. As you'll hear in this episode, Polybion has methods for treating fruit waste to make it economic as a feedstock in their fermentation system to grow cellulose into a leather-like material they call Celium. Already the company is partnered with fashion companies eager to put Celium into their menu of offerings. To sustainably feed and clothe ourselves into the future, it's imperative that we no longer go big with animal agriculture, but instead go small with microbial agriculture. Will Polybion's cellulose leather be a part of the solution? Time will tell. But for now, enjoy hearing the wild ride this company's been on from conception to pivoting technologies to getting a product out onto the market. Discussed in this episode You can see photos of Celium here. CNN on the partnership between Danish fashion brand Ganni and Polybion. Suzanne Lee was an inspiration for Polybion's founders. Ecovative also inspired them, and we did an episode with them too! Plastic-eating fungi offer hope Axel recommends reading Microcosmos and My Inventions. He also recommends watching the original Carl Sagan Cosmos TV series from the 1980s. (The 2014 remake with Neil deGrasse Tyson is also great.) Guillermo González Camarena was an engineer who served as an inspiration to Axel.  More about Axel Gómez-Ortigoza Axel Gómez-Ortigoza was born with an innate fascination for the mysteries of life, the natural world, and the universe, which sparked his lifelong passion for life sciences and finding solutions to complex problems. After completing high school, he decided to carry on the family tradition of engineering that had spanned three generations and pursued a career in bioengineering. With his expertise in Microbiology, Bioinformatics, Cell Culture, Murine Assays, Genetic Engineering, Synthetic Biology, and Origami, Axel became a skilled R&D scientist. At the young age of 22, he and his brother Alexis co-founded Polybion, a New Generation Materials Company, which soon earned Axel a spot as one of MIT Technology Review's Innovators Under 35. Today, he serves as both CEO and CTO of his company, and his groundbreaking work has led to the development of the world's first Bacterial Cellulose Biomanufacturing Facility. Axel's tireless efforts have paved the way for the rapid advancement of bioassembled products, increased sustainability, and a more efficient transition toward a circular economy. He is convinced that the intersection of biology and technology is the key to solving the global health crisis. He envisions a future in which humans and nature can coexist in harmony.

Modern biology is advancing by leaps and bounds, not only in understanding how organisms work, but in learning how to modify them in interesting ways. One exciting frontier is the study of tiny "robots" created from living molecules and cells, rather than metal and plastic. Gizem Gumuskaya, who works with previous guest Michael Levin, has created anthrobots, a new kind of structure made from living human cells. We talk about how that works, what they can do, and what future developments might bring.Blog post with transcript: https://www.preposterousuniverse.com/podcast/2024/04/29/274-gizem-gumuskaya-on-building-robots-from-human-cells/Support Mindscape on Patreon.Gimez Gumuskaya received her Ph.D. from Tufts University and the Harvard Wyss Institute for Biologically-Inspired Engineering. She is currently a postdoctoral researcher at Tufts University. She previously received a dual master's degree in Architecture and Synthetic Biology from MIT.Web siteGoogle scholar publicationsAnthrobots web siteSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.